Analyzing Nano Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Analyzing Nano Drugs



Manufacturers, scientists, and regulators are examining methods for characterizing nanomaterials in drug formulation and production and the need for clear US and international standards in this area. Nano drugs are the subject of a Jan. 14-15, 2014 workshop on the the risks and opportunities of developing nanomaterial drug products, sponsored by the Product Quality Research Institute (PQRI), the US Pharmacopeial Convention, American Association of Pharmaceutical Scientists (AAPS), and FDA. The aim is to encourage more collaboration between academia, industry, and government on relevant research. Experts from FDA and other regulatory authorities will describe efforts to evaluate potential risks from use of nanomaterials in drug products and discuss analytical considerations, impact on stability, safety, and toxicology effects.

This program is timely because of growing interest in FDA moving beyond the examination of nanomaterials in sunscreens and other topicals to opportunities for improving the delivery of treatments for cancer and other serious conditions. The New York Academy of Sciences held a conference in November 2013 on the application of nanotechnology to nanomedicine, featuring experts from the National Characterization Laboratory of the National Cancer Institute discussing the development of new cancer therapies and product characterization. FDA’s 2013 nanotechnology regulatory science research plan outlines a range of activities that would improve staff training, expand laboratory facilities and promote collaborative research on nanotechnology. And the recently issued federal National Nanotechnology Initiative’s 2014 strategic plan describes FDA nano-related initiatives, pointing out the need for more scientific information to better detect and predict the potential impact of nano on drug safety, effectiveness and quality. An FDA blog posted October 24, 2013 describes the agency’s nano activities.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here